 Connection
David Fox to Antibodies, Monoclonal
This is a "connection" page, showing publications David Fox has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.251 |
|
|
|
-
Gurrea-Rubio M, Wu Q, Amin MA, Tsou PS, Campbell PL, Amarista CI, Ikari Y, Brodie WD, Mattichak MN, Muraoka S, Randon PM, Lind ME, Ruth JH, Mao-Draayer Y, Ding S, Shen X, Cooney LA, Lin F, Fox DA. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells. Cancer Immunol Immunother. 2024 Jan 27; 73(2):34.
Score: 0.130
-
Morgan R, Endres J, Behbahani-Nejad N, Phillips K, Ruth JH, Friday SC, Edhayan G, Lanigan T, Urquhart A, Chung KC, Fox DA. Expression and function of aminopeptidase N/CD13 produced by fibroblast-like synoviocytes in rheumatoid arthritis: role of CD13 in chemotaxis of cytokine-activated T cells independent of enzymatic activity. Arthritis Rheumatol. 2015 Jan; 67(1):74-85.
Score: 0.069
-
Parameswaran N, Luo L, Zhang L, Chen J, DiFilippo FP, Androjna C, Fox DA, Ondrejka SL, Hsi ED, Jagadeesh D, Lindner DJ, Lin F. CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma. Leukemia. 2023 10; 37(10):2050-2057.
Score: 0.031
-
Zhang L, Li Y, Qiu W, Bell BA, Dvorina N, Baldwin WM, Singer N, Kern T, Caspi RR, Fox DA, Lin F. Targeting CD6 for the treatment of experimental autoimmune uveitis. J Autoimmun. 2018 06; 90:84-93.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|